A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias
A Phase 3, Double-Blind, Randomized, Multisite Trial Of The Efficacy, Safety, And Tolerability Of The Fixed Combination Torcetrapib/Atorvastatin Administered Orally, Once Daily For 12 Months, Compared To Atorvastatin Alone, Titrated Based On NCEP ATP-III LDL-C Goals In Subjects With Fredrickson Types IIa And IIb Dyslipidemias
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias
For additional information please call: 1-800-718-1021
Inclusion Criteria:
Exclusion Criteria:
Gainsville, Florida 32610, United States
Saint Georges de Beauce, Quebec G5Y 4W1, Canada